|
Mary G. Bolton M.D. Ph.D. served as a consultant to Sunesis on the development of voreloxin before joining the company in 2008 as Vice President Clinical Development. As a medical oncologist she brings more than a decade of industry experience in the clinical development of oncology therapeutics to her new post as Vice President Clinical Development. From 2004 to 2005 Dr. Bolton was Vice President Clinical Development for Sonus Pharmaceuticals Inc. responsible for Phase 1-3 clinical development of the company's lead molecule. Before that she served as Medical Director with ZymoGenetics Inc. and as Medical Director for Cell Therapeutics Inc. leading each company's clinical development programs and providing input on regulatory strategy. From 1999 to 2001 Dr. Bolton led the Herceptin® post-marketing team at Genentech Inc. where she served as a Clinical Scientist. Prior to her industry experience Dr. Bolton spent several years as a practicing oncologist most recently as Assistant Professor of Medical Oncology at the Lombardi Cancer Center Georgetown University Medical Center. She received her Ph.D. from the Department of Physiology at Johns Hopkins University School of Medicine her M.D. from the Medical College of Pennsylvania and a B.A. from Boston University. | 